Wealth Advisors of Tampa Bay LLC bought a new stake in Celgene Co. (NASDAQ:CELG) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 14,506 shares of the biopharmaceutical company’s stock, valued at approximately $1,510,000.
A number of other institutional investors have also added to or reduced their stakes in CELG. First Dallas Securities Inc. increased its position in shares of Celgene by 48.9% in the fourth quarter. First Dallas Securities Inc. now owns 2,663 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 875 shares in the last quarter. Messner & Smith Theme Value Investment Management Ltd. CA increased its position in shares of Celgene by 205.1% in the fourth quarter. Messner & Smith Theme Value Investment Management Ltd. CA now owns 10,516 shares of the biopharmaceutical company’s stock valued at $1,098,000 after buying an additional 7,069 shares in the last quarter. Essex Financial Services Inc. increased its position in shares of Celgene by 14.6% in the fourth quarter. Essex Financial Services Inc. now owns 30,547 shares of the biopharmaceutical company’s stock valued at $3,188,000 after buying an additional 3,901 shares in the last quarter. Buckley Wealth Management LLC purchased a new position in shares of Celgene in the fourth quarter valued at $757,000. Finally, Evermay Wealth Management LLC increased its position in shares of Celgene by 134.3% in the fourth quarter. Evermay Wealth Management LLC now owns 4,423 shares of the biopharmaceutical company’s stock valued at $462,000 after buying an additional 2,535 shares in the last quarter. 78.60% of the stock is owned by institutional investors.
CELG has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a research report on Wednesday, January 17th. William Blair restated a “buy” rating on shares of Celgene in a research report on Wednesday, February 28th. BMO Capital Markets restated a “buy” rating and issued a $147.00 price target on shares of Celgene in a research report on Friday, December 22nd. Credit Suisse Group set a $129.00 price target on Celgene and gave the company a “buy” rating in a research report on Thursday, March 1st. Finally, Stifel Nicolaus set a $130.00 price target on Celgene and gave the company a “buy” rating in a research report on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $128.22.
In other news, insider Mark J. Alles acquired 3,260 shares of Celgene stock in a transaction dated Thursday, February 8th. The shares were acquired at an average cost of $91.90 per share, with a total value of $299,594.00. Following the purchase, the insider now directly owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director James J. Loughlin sold 9,250 shares of Celgene stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $92.01, for a total value of $851,092.50. The disclosure for this sale can be found here. Insiders sold a total of 41,120 shares of company stock valued at $3,879,509 in the last 90 days. 0.95% of the stock is owned by company insiders.
Shares of Celgene Co. (NASDAQ:CELG) opened at $88.53 on Tuesday. The company has a quick ratio of 4.80, a current ratio of 4.99 and a debt-to-equity ratio of 2.29. The company has a market capitalization of $67,402.45, a PE ratio of 24.73, a price-to-earnings-growth ratio of 0.63 and a beta of 1.58. Celgene Co. has a fifty-two week low of $86.55 and a fifty-two week high of $147.17.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm’s revenue was up 16.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.61 EPS. equities research analysts forecast that Celgene Co. will post 7.66 earnings per share for the current fiscal year.
Celgene declared that its board has authorized a stock repurchase plan on Wednesday, February 14th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: “14,506 Shares in Celgene Co. (CELG) Purchased by Wealth Advisors of Tampa Bay LLC” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/03/20/14506-shares-in-celgene-co-celg-purchased-by-wealth-advisors-of-tampa-bay-llc.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.